WO2013127539A3 - Pharmazeutische formulierung enthaltend flupirtin - Google Patents
Pharmazeutische formulierung enthaltend flupirtin Download PDFInfo
- Publication number
- WO2013127539A3 WO2013127539A3 PCT/EP2013/000615 EP2013000615W WO2013127539A3 WO 2013127539 A3 WO2013127539 A3 WO 2013127539A3 EP 2013000615 W EP2013000615 W EP 2013000615W WO 2013127539 A3 WO2013127539 A3 WO 2013127539A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- flupirtin
- pharmaceutical formulation
- formulation containing
- active ingredient
- microtablets
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201491477A EA201491477A1 (ru) | 2012-03-02 | 2013-03-01 | Фармацевтические составы, содержащие флупиртин |
CA2864876A CA2864876A1 (en) | 2012-03-02 | 2013-03-01 | Pharmaceutical formulations |
CN201380012290.5A CN104302277A (zh) | 2012-03-02 | 2013-03-01 | 含有氟吡汀的药物制剂 |
NZ628867A NZ628867A (en) | 2012-03-02 | 2013-03-01 | Pharmaceutical formulation containing flupirtine |
EP13708685.6A EP2819658A2 (de) | 2012-03-02 | 2013-03-01 | Pharmazeutische formulierung enthaltend flupirtin |
AU2013225352A AU2013225352A1 (en) | 2012-03-02 | 2013-03-01 | Pharmaceutical formulation containing flupirtin |
US14/382,231 US20150072006A1 (en) | 2012-03-02 | 2013-03-01 | Pharmaceutical Formulations |
JP2014559128A JP2015508789A (ja) | 2012-03-02 | 2013-03-01 | 医薬製剤 |
BR112014021433A BR112014021433A2 (pt) | 2012-03-02 | 2013-03-01 | formulações farmacêuticas |
MX2014010460A MX2014010460A (es) | 2012-03-02 | 2013-03-01 | Formulaciones farmaceuticas que contienen flupirtina. |
ZA2014/06407A ZA201406407B (en) | 2012-03-02 | 2014-09-01 | Pharmaceutical formulation containing flupirtin |
HK15105588.0A HK1204945A1 (en) | 2012-03-02 | 2015-06-12 | Pharmaceutical formulation containing flupirtin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102012004065.2 | 2012-03-02 | ||
DE102012004065 | 2012-03-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013127539A2 WO2013127539A2 (de) | 2013-09-06 |
WO2013127539A3 true WO2013127539A3 (de) | 2013-12-19 |
Family
ID=47845907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2013/000615 WO2013127539A2 (de) | 2012-03-02 | 2013-03-01 | Pharmazeutische formulierungen |
Country Status (13)
Country | Link |
---|---|
US (1) | US20150072006A1 (de) |
EP (1) | EP2819658A2 (de) |
JP (1) | JP2015508789A (de) |
CN (1) | CN104302277A (de) |
AU (1) | AU2013225352A1 (de) |
BR (1) | BR112014021433A2 (de) |
CA (1) | CA2864876A1 (de) |
EA (1) | EA201491477A1 (de) |
HK (1) | HK1204945A1 (de) |
MX (1) | MX2014010460A (de) |
NZ (1) | NZ628867A (de) |
WO (1) | WO2013127539A2 (de) |
ZA (1) | ZA201406407B (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2664693C1 (ru) * | 2017-10-05 | 2018-08-21 | Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ предоперационной подготовки пациентов к офтальмологическим операциям |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0615754A1 (de) * | 1993-03-18 | 1994-09-21 | ASTA Medica Aktiengesellschaft | Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe |
EP1795186A2 (de) * | 2005-11-08 | 2007-06-13 | AWD.pharma GmbH & Co.KG | Flupirtin umfassende Arzneimittelzubereitung mit kontrollierter Wirkstofffreisetzung |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19541405A1 (de) * | 1995-11-07 | 1997-05-15 | Asta Medica Ag | Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen |
NZ513037A (en) * | 1999-01-29 | 2003-05-30 | Disphar Internat B | Coated sustained release pharmaceutical composition for the release of an agent in the gastrointestinal tract |
US6610324B2 (en) * | 1999-04-07 | 2003-08-26 | The Mclean Hospital Corporation | Flupirtine in the treatment of fibromyalgia and related conditions |
US8334263B2 (en) * | 2003-12-16 | 2012-12-18 | Raymond Nadeson | Analgesic methods and compositions |
US7553858B2 (en) * | 2003-12-17 | 2009-06-30 | Meda Pharma Gmbh & Co. Kg | Combination of flupirtine and tramadol |
DE102006006532B4 (de) * | 2006-02-10 | 2007-11-08 | Biogenerics Pharma Gmbh | Pharmazeutische Zubereitung |
JP2009539769A (ja) * | 2006-06-02 | 2009-11-19 | アリアド ジーン セラピューティクス インコーポレイテッド | カペシタビン併用療法 |
US20080279930A1 (en) * | 2007-05-07 | 2008-11-13 | Bernd Terhaag | Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof |
-
2013
- 2013-03-01 MX MX2014010460A patent/MX2014010460A/es unknown
- 2013-03-01 WO PCT/EP2013/000615 patent/WO2013127539A2/de active Application Filing
- 2013-03-01 CN CN201380012290.5A patent/CN104302277A/zh active Pending
- 2013-03-01 JP JP2014559128A patent/JP2015508789A/ja active Pending
- 2013-03-01 BR BR112014021433A patent/BR112014021433A2/pt not_active IP Right Cessation
- 2013-03-01 CA CA2864876A patent/CA2864876A1/en not_active Abandoned
- 2013-03-01 AU AU2013225352A patent/AU2013225352A1/en not_active Abandoned
- 2013-03-01 US US14/382,231 patent/US20150072006A1/en not_active Abandoned
- 2013-03-01 EP EP13708685.6A patent/EP2819658A2/de not_active Withdrawn
- 2013-03-01 NZ NZ628867A patent/NZ628867A/en not_active IP Right Cessation
- 2013-03-01 EA EA201491477A patent/EA201491477A1/ru unknown
-
2014
- 2014-09-01 ZA ZA2014/06407A patent/ZA201406407B/en unknown
-
2015
- 2015-06-12 HK HK15105588.0A patent/HK1204945A1/xx unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0615754A1 (de) * | 1993-03-18 | 1994-09-21 | ASTA Medica Aktiengesellschaft | Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe |
EP1795186A2 (de) * | 2005-11-08 | 2007-06-13 | AWD.pharma GmbH & Co.KG | Flupirtin umfassende Arzneimittelzubereitung mit kontrollierter Wirkstofffreisetzung |
Also Published As
Publication number | Publication date |
---|---|
EP2819658A2 (de) | 2015-01-07 |
JP2015508789A (ja) | 2015-03-23 |
BR112014021433A2 (pt) | 2017-07-18 |
NZ628867A (en) | 2016-03-31 |
AU2013225352A1 (en) | 2014-09-18 |
WO2013127539A2 (de) | 2013-09-06 |
HK1204945A1 (en) | 2015-12-11 |
US20150072006A1 (en) | 2015-03-12 |
MX2014010460A (es) | 2014-10-13 |
EA201491477A1 (ru) | 2015-02-27 |
CN104302277A (zh) | 2015-01-21 |
ZA201406407B (en) | 2016-01-27 |
CA2864876A1 (en) | 2013-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201406141UA (en) | Immortalized stem cells and medicinal composition and medicinal preparation comprising product thereof as active ingredient | |
WO2014205389A8 (en) | Nuclear transport modulators and uses thereof | |
WO2015018380A3 (en) | Therapeutic nanoparticles and the preparation methods thereof | |
EP3067059A4 (de) | Pharmazeutische zusammensetzung zur vorbeugung oder behandlung von schilddrüsenerkrankungen mit extrakt aus der lonicera caerulea l. var. edulis-frucht als wirkstoff | |
IN2015DN03984A (de) | ||
EP3034082A4 (de) | Pharmazeutische zusammensetzung zur behandlung oder prävention neuropsychiatrischer krankheiten mit flavon-6-c-glucose-derivaten als wirkstoffen | |
EP3093023A4 (de) | Pharmazeutische zusammensetzung zur krebsbehandlung und pharmazeutische zubereitung zur krebsbehandlung mit dieser zusammensetzung als wirkstoff | |
MX2017004772A (es) | Composiciones y métodos para la administración fisiológica utilizando cannabidiol. | |
EP3138834A4 (de) | Cyclohexenderivat, herstellungsverfahren dafür und pharmazeutische zusammensetzung zur vorbeugung oder behandlung von stoffwechselkrankheiten damit als wirkstoff | |
MX2016001422A (es) | Composicion farmaceutica de fingolimod. | |
PH12015502556A1 (en) | Modified release formulation | |
WO2015001163A3 (es) | Nanopartículas lipídicas para la cicatrización de heridas | |
EP3352750A4 (de) | Cyclohexenderivat, herstellungsverfahren dafür und pharmazeutische zusammensetzung zur vorbeugung oder behandlung von stoffwechselkrankheiten damit als wirkstoff | |
EP2875814A4 (de) | Flüssige zusammensetzung mit wirkstoff auf taxanbasis, verfahren zur herstellung davon und flüssiges arzneimittel | |
EP2871187A4 (de) | Neuartige verbindung oder pharmazeutisch unbedenkliches salz davon und pharmazeutische zusammensetzung damit als wirkstoff | |
EP3158998A4 (de) | Pharmazeutische zubereitung mit entecavir als wirkstoff und herstellungsverfahren dafür | |
PH12015501377A1 (en) | Solid unit with high fexofenadine content and process for the preparation thereof | |
EP3311817A4 (de) | Pharmazeutische zusammensetzung zur vorbeugung und behandlung von augenerkrankungen mit imatinib als wirkstoff | |
MX364652B (es) | Formulacion farmaceutica que comprende ciclesonida. | |
EP3167893A4 (de) | Pharmazeutische zusammensetzung mit spirulina-maxima-extrakt als wirkstoff zur vorbeugung und behandlung von netzhauterkrankungen | |
EP2886112A4 (de) | Zusammensetzung zur prävention oder behandlung von augenerkrankungen mit s-allyl-l-cystein als wirkstoff und pharmazeutische formulierung damit | |
EP2476420B8 (de) | Pharmazeutische zusammensetzung mit antimikrobieller und schnell heilender wirkung zur externen verabreichung sowie herstellungsverfahren dafür | |
WO2015022560A8 (en) | Stable pharmaceutical composition containing bisoprolol and ramipril | |
WO2013127539A3 (de) | Pharmazeutische formulierung enthaltend flupirtin | |
NZ702849A (en) | Genotype- or phenotype-based drug formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13708685 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2864876 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 234235 Country of ref document: IL |
|
REEP | Request for entry into the european phase |
Ref document number: 2013708685 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013708685 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14382231 Country of ref document: US Ref document number: MX/A/2014/010460 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2014559128 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201491477 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 2013225352 Country of ref document: AU Date of ref document: 20130301 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014021433 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014021433 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140828 |